Ads
related to: phenytoin intravenous use in cancer patients
Search results
Results From The WOW.Com Content Network
Intravenous use is contraindicated in patients with sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, Stokes-Adams syndrome, or hypersensitivity to phenytoin, other hydantoins or any ingredient in the respective formulation.
Purple glove syndrome is caused by the intravenous anticonvulsant phenytoin. [3] This medication has many already established neurological side effects. However, glove syndrome is a rare, with prevalence ranging from 1.7% to 5.9%, but has very serious adverse effect that may lead to limb amputations.
It is taken alone, or in combination with complementary agents such as phenytoin, in commercial animal euthanasia injectable solutions. [5] [6] Pentobarbital sodium (CAS No. 57-33-0) In the Netherlands, pentobarbital is part of the standard protocol for physician-assisted suicide for self-administration by the patient. [11]
Phenytoin/pentobarbital (trade name Beuthanasia-D Special) is an animal drug product used for euthanasia, which contains a mixture of phenytoin and pentobarbital. [1] It is administered as an intravenous injection to give animals a quick and humane death.
Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein.The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not—due to reduced mental states or otherwise—consume food or water by mouth.
Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost.
Ad
related to: phenytoin intravenous use in cancer patients